Next Article in Journal
Addendum: Bedoya-Pérez, L.P. et al. Role of UPR Pathway in Defense Response of Aedes aegypti against Cry11Aa Toxin from Bacillus thuringiensis. Int. J. Mol. Sci. 2013, 14, 8467–8478
Next Article in Special Issue
The Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome System
Previous Article in Journal
Prolactin: Friend or Foe in Central Nervous System Autoimmune Inflammation?
Previous Article in Special Issue
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(12), 2029;

TP53/MicroRNA Interplay in Hepatocellular Carcinoma

Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, 40138 Bologna, Italy
Department of Medical and Surgical Sciences, Bologna University, 40138 Bologna, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Tomoo Iwakuma
Received: 13 October 2016 / Revised: 23 November 2016 / Accepted: 28 November 2016 / Published: 2 December 2016
(This article belongs to the Special Issue Emerging Non-Canonical Functions and Regulation of p53)
Full-Text   |   PDF [1359 KB, uploaded 2 December 2016]   |  


The role of microRNAs as oncogenes and tumor suppressor genes has emerged in several cancers, including hepatocellular carcinoma (HCC). The pivotal tumor suppressive role of p53-axis is indicated by the presence of inactivating mutations in TP53 gene in nearly all cancers. A close interaction between these two players, as well as the establishment of complex p53/miRNAs loops demonstrated the strong contribution of p53-effector miRNAs in enhancing the p53-mediated tumor suppression program. On the other hand, the direct and indirect targeting of p53, as well as the regulation of its stability and activity by specific microRNAs, underlie the importance of the fine-tuning of p53 pathway, affecting the cell fate of damaged/transformed cells. The promising results of miRNAs-based therapeutic approaches in preclinical studies and their entrance in clinical trials demonstrate the feasibility of this strategy in several diseases, including cancer. Molecularly targeted drugs approved so far for HCC treatment show intrinsic or acquired resistances with disease progression in many cases, therefore the identification of effective and non-toxic agents for the treatment of HCC is actually an unmet clinical need. The knowledge of p53/miRNA inter-relations in HCC may provide useful elements for the identification of novel combined approaches in the context of the “personalized-medicine” era. View Full-Text
Keywords: hepatocellular carcinoma (HCC); microRNA; p53 hepatocellular carcinoma (HCC); microRNA; p53

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Pollutri, D.; Gramantieri, L.; Bolondi, L.; Fornari, F. TP53/MicroRNA Interplay in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2016, 17, 2029.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top